Abstract: A nuclear fusion system comprises: a muon generation unit to generate negative muons including electron and positron accelerators for generating electron and positron beams; a gas supply unit to supply to circulate gaseous deuterium or gaseous deuterium-tritium mixture as raw material gas; a Laval nozzle to accelerate the raw material gas to supersonic velocity; and a shock wave cone connected to the Laval nozzle to introduce the raw material gas accelerated to supersonic velocity to generate an oblique shock wave, the raw material gas accelerated to supersonic velocity being introduced into the shock wave cone to generate the oblique shock wave, the oblique shock wave being decelerated to create a high-density gas target in an in-flight manner, the muons generated as a result of causing electrons and positrons to collide with each other being introduced into the high-density gas target thereby to cause a muon-catalyzed nuclear fusion reaction to occur.

Abstract: An anti-HIV agent containing, as an active ingredient, ex, 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

Abstract: Provided are a toxin separator and the like which are capable of selectively separating toxin present in a biological fluid by binding to protein, from the toxin and the protein. The toxin separator of the present invention also includes activated carbon of which a pore volume of pores having a pore diameter from 1.4 to 35 nm as measured by a nitrogen adsorption method is 0.06 cm3/g or greater.

Abstract: Provided are a toxin separator and the like which are capable of selectively separating toxin present in a biological fluid by binding to protein, from the toxin and the protein. The toxin separator of the present invention also includes activated carbon of which a pore volume of pores having a pore diameter from 1.4 to 35 nm as measured by a nitrogen adsorption method is 0.06 cm3/g or greater.

Abstract: An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

Abstract: An object of the present invention is to provide a competitive EIA method capable of quantitatively measuring indoxyl sulfate in blood. The problem described above can be solved by an indoxyl sulfate measurement method based on a competitive method comprising: (1) a step in which albumin in a specimen is pretreated; (2) a specimen-antibody reaction step in which the pretreated specimen and anti-indoxyl sulfate antibodies are brought into contact with each other in the substantial absence of exogenous mammalian albumin; (3) an immobilized IS-antibody reaction step in which the specimen-antibody reaction solution is brought into contact, in the substantial absence of exogenous mammalian albumin, with an immobilized insoluble support in which indoxyl sulfate is immobilized and then blocked with a buffer solution containing substantially no mammalian albumin; and (4) a step in which anti-indoxyl sulfate antibodies which have bonded to the immobilized insoluble support are detected.

Abstract: A storage apparatus includes a memory that stores a job management information that registers a write job corresponding to a write command upon receiving the write command from other apparatus, a cache memory that stores data designated as target data by the write command, a storage drive that records the data stored in the cache memory to a storage medium based on the write job registered in the job management information, and a controller that controls a timing to output to the other apparatus a completion report of the write command based on a load condition of the storage device related to an accumulation count of write job acquired from the job management information.

Abstract: An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

Abstract: A storage control device includes a processor. The processor is configured to receive commands requesting access to a first storage. The processor is configured to detect, among the received commands, a monitoring command requesting access for monitoring to the first storage. The processor is configured to restrict access to the first storage in response to the detected monitoring command.

Abstract: An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

Abstract: A library apparatus includes a medium name storage unit that stores medium name conversion information in which a virtual medium name specifying a storage medium in a read/write request from a host is related to a real medium name specifying the storage medium in the library apparatus, a conveying mechanism unit that conveys the storage medium, a drive that reads/writes data from/to the storage medium conveyed by the conveying mechanism unit in response to the received read/write request, a conversion unit that converts the virtual medium name included in the received read/write request to the real medium name on the basis of the medium name conversion information stored in the medium name storage unit, and a conveying mechanism control unit that controls the conveying mechanism unit to convey the storage medium having the real medium name converted by the conversion unit to the drive.

Abstract: A storage apparatus includes a memory that stores a job management information that registers a write job corresponding to a write command upon receiving the write command from other apparatus, a cache memory that stores data designated as target data by the write command, a storage drive that records the data stored in the cache memory to a storage medium based on the write job registered in the job management information, and a controller that controls a timing to output to the other apparatus a completion report of the write command based on a load condition of the storage device related to an accumulation count of write job acquired from the job management information.

Abstract: An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

Abstract: A library apparatus includes a medium name storage unit that stores medium name conversion information in which a virtual medium name specifying a storage medium in a read/write request from a host is related to a real medium name specifying the storage medium in the library apparatus, a conveying mechanism unit that conveys the storage medium, a drive that reads/writes data from/to the storage medium conveyed by the conveying mechanism unit in response to the received read/write request, a conversion unit that converts the virtual medium name included in the received read/write request to the real medium name on the basis of the medium name conversion information stored in the medium name storage unit, and a conveying mechanism control unit that controls the conveying mechanism unit to convey the storage medium having the real medium name converted by the conversion unit to the drive.

Abstract: An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

Abstract: A drive control apparatus receives an instruction from an upper unit, to mount a predetermined medium onto a predetermined drive unit. If a combination of the predetermined medium and the predetermined drive unit is determined as inappropriate, the drive control unit replies to the upper unit that the predetermined drive unit cannot be used. A combination of a medium and a drive is appropriate if both, the medium and the drive are suitable for any one of encrypted and unencrypted data.

Abstract: A drive control apparatus receives an instruction from an upper unit, to mount a predetermined medium onto a predetermined drive unit. If a combination of the predetermined medium and the predetermined drive unit is determined as inappropriate, the drive control unit replies to the upper unit that the predetermined drive unit cannot be used. A combination of a medium and a drive is appropriate if both, the medium and the drive are suitable for any one of encrypted and unencrypted data.

Abstract: An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

Abstract: An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

Abstract: A fuel pump has a cam shaft for actuating a pump element to deliver fuel under pressure to an engine. One end of the cam shaft protrudes outside of a pump housing, to which a coupling block is fixedly secured. At least two axially extending threaded holes are formed on the coupling block, and also at least two axially extending through holes are formed on a driving gear for engaging a ring gear of the engine. A head-less locking bolt is screwed into one of threaded holes until the front end thereof abut on the pump housing so that the coupling block is held at a proper position. Thereafter, the driving gear is mounted to the coupling block so that the rear end of the head-less bolt is inserted into one of the through holes and at the same time the driving gear engages with the ring gear of the engine in order to couple the fuel pump to the engine with a synchronous relationship.